Nanoparticle-based multivalent human antibodies offer potent and broad neutralization against Omicron sublineages
作者机构：State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics National Institute of Diagnostics and Vaccine Development in Infectious DiseasesSchool of Public HealthSchool of Life SciencesXiamen UniversityXiamenChina Xiang An Biomedicine LaboratoryXiamenChina and 3 Research Unit of Frontier Technology of Structural Vaccinology of Chinese Academy of Medical SciencesXiamenChina
出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗(英文))
年 卷 期：2023年第8卷第9期
页 面：3909-3912页
核心收录：
学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 100102[医学-免疫学] 10[医学]
基 金：This work was supported by grants from the National Key Research and Development Program of China(grant no.2022YFC0869900) the National Natural Science Foundation of China(grant nos.81991491,82272305) the Fundamental Research Funds for the Central Universities(grant no.20720220006) China Postdoctoral Science Foundation(grant nos.2022M722659) CAMS Innovation Fund for Medical Sciences(grant no.2019RU022).
主 题：antibodies acute respiratory
摘 要：Dear Editor As of January 2023,coronavirus disease 2019(COVID-19)induced by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused more than 6.7 million deaths,with SARS-CoV-2 variants continuing to alter the trajectory of the COVID-19 pandemic.Indeed,the prevalence of the newly emergent Omicron sublineages,particularly BA.4/5 and XBB,has highlighted the critical need for the design and production of broadly potent neutralization antibodies to efficiently combat SARS-CoV-2 variants.Neutralizing antibodies(nAbs)XMA01,XMA04,and XMA09,which target noncompeting antigenic sites in RBD(receptor binding domain),exhibit high neutralization potency against earlier disease variants(Supplementary Fig.1a–d),as previously reported by us.
维普期刊数据库